Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial
Abstract
We performed the largest randomized, placebo‐controlled clinical trial to date (N = 112, 12‐week intervention) to investigate the effects and safety of resveratrol supplementation on liver fat content and cardiometabolic risk parameters in overweight and obese and insulin‐resistant subjects. At baseline the variability in liver fat content was very large, ranging from 0.09% to 37.55% (median, 7.12%; interquartile range, 3.85%‐12.94%). Mean (SD) liver fat content was 9.22 (6.85) % in the placebo group and 9.91 (7.76) % in the resveratrol group. During the study liver fat content decreased in the placebo group (−0.7%) but not in the resveratrol group (−0.03%) (differences between groups: P = .018 for the intention‐to‐treat [ITT] population; N = 54, resveratrol, N = 54, placebo and P = .0077 for the per protocol [PP] population). No effects of resveratrol supplementation on cardiometabolic risk parameters were observed. Resveratrol supplementation was well tolerated and safe. In conclusion, these data suggest that resveratrol supplementation is safe and that it does not considerably impact liver fat content or cardiometabolic risk parameters in humans.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the 2018 largest randomized trial, resveratrol 75 mg twice daily for 12 weeks in overweight/obese patients with insulin resistance produced no changes in cardiometabolic risk markers or liver fat content.
“No changes in cardiometabolic risk markers and liver fat content were found.”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [43]
In the 2018 trial, resveratrol was well tolerated and no adverse events were reported.
“Resveratrol was well tolerated and no adverse events were reported [43].”
From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [43]
Cites
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · see citing works
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320 · see citing works
Self-citationCauses, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans
Stefan, N., Schick, F., & Häring, H.-U. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.008 · Cited by 575 · cited 1× · see citing works
“Diastolic blood pressure (mm Hg) 88 (12) 88 (9) 88 (10) 86 (10) .”
Self-citationHigh-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455 · see citing works
Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C. C., Kunz, I., Fanelli, F. R., Patterson, B. W., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.015 · Cited by 381 · see citing works
Self-citationFaghihzadeh, F., Adibi, P., Rafiei, R., & Hekmatdoost, A. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.09.005 · Cited by 345 · see citing works
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341 · see citing works
Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., Konigsrainer, A., Konigsrainer, I., Krober, S., Niess, A., et al. (2009) · Gut · doi:10.1136/gut.2008.151977 · Cited by 273 · see citing works
Self-citationPhenotypes of prediabetes and stratification of cardiometabolic risk
Stefan, N., Fritsche, A., Schick, F., & Häring, H.-U. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00082-6 · Cited by 208 · see citing works
Self-citationMaximos, M., Bril, F., Portillo-Sánchez, P., Lomonaco, R., Orsak, B., Biernacki, D., Suman, A., Weber, M. H., & Cusi, K. J. (2014) · Hepatology · doi:10.1002/hep.27395 · Cited by 196 · see citing works
Timmers, S., de Ligt, M., Esther Phielix, E., van de Weijer, T., Hansen, J., Moonen‐Kornips, E., Schaart, G., Kunz, I., Hesselink, M. K. C., Schrauwen‐Hinderling, V. B., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0499 · Cited by 138 · see citing works
Self-citationResveratrol and obesity: can resveratrol relieve metabolic disturbances?
de Ligt, M., Timmers, S., & Schrauwen, P. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.012 · Cited by 135 · see citing works
Stefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., Hwang, J., Nowotny, P., KAHL, S., Harreiter, J., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70170-0 · Cited by 114 · see citing works
Self-citationElgebaly, A. S., Radwan, I., Aboelnas, M. M., Ibrahim, H. H., Eltoomy, M., Atta, A. A., Mesalam, H. A., Sayed, A. A. E., & Othman, A. A. (2017) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.261.ely · Cited by 92 · see citing works
Simão, F., Pagnussat, A. S., Seo, J. H., Navaratna, D., Leung, W., Lok, J. M., Guo, S., Waeber, C., Salbego, C. G., & Lo, E. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.2 · Cited by 71 · see citing works
Zhang, H., Pan, L., Ma, Z., Chen, Z., Huang, Z., Sun, Q., Lü, Y., Han, C., Lin, M., Li, X., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12809 · Cited by 62 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review
Meng, X., Zhou, J., Zhao, C.-N., Gan, R.-Y., & Li, H.-B. (2020) · Foods · doi:10.3390/foods9030340 · Cited by 387 · see citing works
The Role of Resveratrol Administration in Human Obesity
Mongioì, L. M., La Vignera, S., Cannarella, R., Cimino, L., Compagnone, M., Condorelli, R. A., & Calogero, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094362 · Cited by 71 · see citing works
Zemel, M. B. (2020) · Journal of Medicinal Food · doi:10.1089/jmf.2020.0105 · Cited by 12 · see citing works
- Authors
- Kantartzis, K., Fritsche, L., Bombrich, M., Machann, J., Schick, F., Staiger, H., Kunz, I., Schoop, R., Lehn‐Stefan, A., Heni, M., Peter, A., Fritsche, A., Häring, H., & Stefan, N.
- Affiliations
- Department of Internal Medicine IV, Division of Endocrinology, Diabetology, Vascular Medicine, Nephrology and Clinical Chemistry University of Tübingen Tübingen Germany
- Helmholtz Munich (DE)
- University of Tübingen (DE)
- DSM (Switzerland) (CH)
- Corresponding author
- Stefan, Norbert
- ORCID
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-03-22
- Volume
- 20
- Issue
- 7
- Pages
- 1793-1797
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2791089458
- Cited by
- 87
- References
- 16
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 15 · 2023: 7 · 2022: 11 · 2021: 18 · 2020: 17 · 2019: 5 · 2018: 5
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Funders
- University Hospital of Tübingen, Germany
- DSM Nutritional Products, Kaiseraugst, Ltd, Switzerland
- Deutsches Zentrum für Diabetesforschung
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- resveratrol, dietary supplementation, liver fat, hepatic steatosis, insulin resistance, overweight, obesity, cardiometabolic risk, safety and tolerability
- MeSH terms
- Resveratrol, Adult, Aged, Antioxidants, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Insulin Resistance, Liver, Male, Middle Aged, Dietary Supplements, Intra-Abdominal Fat, Overweight, Non-alcoholic Fatty Liver Disease, Proton Magnetic Resonance Spectroscopy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
